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Abstract
Introduction: To generalize safety and efficacy findings, it is essential that diverse populations are well represented in Alzheimer’s disease (AD) drug trials. In this review, we
aimed to investigate participant diversity in disease-modifying AD trials over time, and
the frequencies of participant eligibility criteria.
Methods: A systematic review was performed using Medline, Embase, the Cochrane
Library, and Clinicaltrials.gov, identifying 2247 records.
Results: In the 101 included AD trials, participants were predominantly White (median
percentage: 94.7%, interquartile range: 81.0–96.7%); and this percentage showed no
significant increase or decrease over time (2001–2019). Eligibility criteria such as
exclusion of persons with psychiatric illness (78.2%), cardiovascular disease (71.3%)
and cerebrovascular disease (68.3%), obligated caregiver attendance (80.2%), and specific Mini-Mental State Examination scores (90.1%; no significant increase/decrease
over time) may have led to a disproportionate exclusion of ethnoracially diverse individuals.
Discussion: Ethnoracially diverse participants continue to be underrepresented in AD
clinical trials. Several recommendations are provided to broaden eligibility criteria.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.
Alzheimer’s Dement. 2021;1–14.
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INTRODUCTION

out restrictions on the year of publication or location of the trial. Search
terms included different terms for AD and mild cognitive impairment

Although ethnoracially diverse individuals are at an increased risk of

(MCI), terms referring to disease-modifying drugs, terms related to

developing Alzheimer’s disease (AD) dementia,1–4 these populations

amyloid beta (Aβ) and tau, and different terms for phase II and phase

are systematically underrepresented in AD clinical trials.5–7 To gener-

III trials (for the complete lists of the search terms used, see Text S1 in

alize safety and efficacy findings from drug trials to the general pop-

supporting information). Studies were included up to December 2019.

ulation, it is essential to include a diverse population, as differences

Two independent authors screened all collected study data (JS and SF).

in pharmacokinetics and pharmacodynamics across diverse popula-

Disagreement was resolved by a consensus agreement together with

tions may impact treatment effect and safety;8,9 for instance, drug

JMP. The PRISMA (Preferred Reporting Items for Systematic Reviews

metabolism rates may differ.6 The lack of diversity among clinical trial

and Meta-Analyses) guidelines16 were followed, except for an assess-

participants is often attributed to enrolling and retaining practices,

ment of the risk of bias—this step was omitted, as the aim was not to

such as recruitment strategies that do not account for factors that play

review or summarize the treatment effect reported in the included clin-

a role in diverse populations, including mistrust and worry because

ical trials.

of historical racism in medical research or the possibility of injury or
complications.10
Although recruitment factors should be taken into consideration,

2.2

Eligibility criteria

other explanations need to be considered as well, especially because
a number of studies have indicated that people from underrepre-

To be included in the review:

sented populations may be equally willing to participate in health
research.11,12 One important potential cause is that there are inherent

1. The study needed to be a planned, ongoing, completed, or early ter-

features of AD-clinical trial eligibility criteria that lead to a dispropor-

minated phase II or phase III drug trial for patients with AD demen-

tionate and systemic exclusion of underrepresented populations.13,14

tia, prodromal AD (early AD stage 317 ), or amnestic MCI (aMCI).

In 1997, Schneider et

al.14

demonstrated that applying the eligibility

2. The experimental drug was a disease-modifying treatment.

criteria of typical AD clinical trials to a Californian memory clinic popu-

Disease-modifying was defined as targeting the pathogenic steps

lation led to a systematic underrepresentation of people who are older,

in the Aβ or tau pathways. This includes passive vaccination, mon-

female, ethnoracially diverse, lower educated, and less wealthy; they

oclonal antibodies, agents disrupting accumulation or aggregation,

provided several suggestions to improve provisional eligibility, such as

and agents increasing clearance. As no agreed-upon standards

a wider range of allowed scores on the Mini-Mental State Examination

are currently available that definitively delineate which drugs are

(MMSE15 ) or by allowing more patients with (mild) behavioral and psy-

considered disease-modifying, drug mechanisms were confirmed

chological symptoms to participate.

by consulting relevant literature (e.g., Galimberti and Scarpini18 )

This systematic review aims to take a closer look at diversity in clinical trials and eligibility criteria. The first goal was to investigate the

and examining trial features (e.g., outcomes measuring amyloid
clearance).

level of participant diversity in AD clinical trials in the decades after the
publication of Schneider et al.14 The second goal was to identify which

To adequately capture recent developments; collate study results;

eligibility criteria have been used and how these eligibility criteria were

and provide a clearly delineated, concise set of recommendations,

defined. Third, we aimed to assess whether the use of criteria related

we focused on a homogeneous set of trials and excluded several

to cognitive and neuropsychiatric instruments such as the MMSE have

other types of trials and study populations from this review. First, we

changed over time, as these were highlighted by Schneider et al.14 as

excluded studies focusing on other forms of dementia. Second, we

particularly problematic. Last, we will discuss how some eligibility cri-

excluded AD prevention trials (e.g., lifestyle intervention trials) and

teria may have affected diversity levels in AD clinical trials.

studies in preclinical AD (early AD stages 1–217 ) as these types of trials present with unique challenges and eligibility criteria. Third, we
excluded studies focused on symptomatic treatment of AD, including

2

METHODS

studies of acetylcholinesterase inhibitors—tacrine, donepezil, rivastigmine, and galantamine—and memantine. Fourth, we excluded tri-

2.1

Search strategy

als investigating herbal and dietary treatments (e.g., vitamin supplements, olive oil, huperzine). Conference abstracts, dissertations, com-

We performed a systematic review using Medline (which includes

ments, editorials, book chapters, white papers, and reviews were also

PubMed), Embase, the Cochrane Library, and ClinicalTrials.gov, with-

excluded.

3

FRANZEN ET AL .

2.3

Data extraction
RESEARCH IN CONTEXT

For each included study, all available study protocol sources—that is,
1. Systematic review: We reviewed the published literature

published papers or National Clinical Trial (NCT) database, European

and clinical trial registries to examine participant diver-

Union Drug Regulating Authorities Clinical Trial Database (EudraCT),

sity in Alzheimer’s disease drug trials, as well as develop-

and Australian New Zealand Clinical Trial Registry (ANZCTR) clinical

ments in eligibility criteria for these trials. The trials cov-

trial registrations—identified in the search were used for data extrac-

ered a time period from 2001–2019.

tion. When available, the year that the study was first posted, the study

2. Interpretation: Study samples in AD trials were predom-

phase, the investigational drug, the inclusion and exclusion criteria, the

inantly white, and participant diversity did not change

number of recruited participants, and participant demographics were

over time. Several characteristics of eligibility criteria may

recorded. Information was compiled from all available sources to cre-

lead to systemic exclusion of diverse populations, such as

ate the most complete account of each study’s design and study sample.

the use of specific cognitive tests, requirements regarding
language fluency, education, or caregiver attendance, and

2.4

the exclusion of patients with comorbid conditions.

Data analysis

3. Future directions: This review highlights several eligibility criteria that require more research/consensus, such as

Participant eligibility criteria were divided into three main categories:

how to best operationalize medical conditions and which

(1) criteria related to medical conditions; (2) criteria related to under-

cognitive and clinical tests may best be used in diverse

going specific study procedures, such as neuropsychological tests and

populations. In addition, it highlights the need for revision

brain scans; and (3) criteria based on diagnostic tests and question-

of race/ethnicity categorization and for better reporting

naire outcomes. Analyses were mostly descriptive. We used Cochran-

of diversity-related data.

Armitage trend tests (using the CATT package in R) to assess trends
over time for binary variables, that is, whether a criterion was used in
the trial or not. Spearman correlations were used to analyze associations between the study start year and continuous variables.

3.1
3

RESULTS

Diversity in clinical trial participants

Of the 101 trials, most had one or more study site(s) in North America
(79.2%) or Europe (60.4%), and less frequently Asia (36.6%), or Ocea-

We identified 2247 records. The review process is summarized in

nia (32.7%); even fewer trials included study sites in South America

the PRISMA flowchart in Figure 1. After deduplication, 1777 records

(14.9%) or Africa (6.9%). Race/ethnicity data of the enrolled partici-

remained; these records were screened on title and abstract. If the

pants was available for less than half of the clinical trials (46 stud-

topic of the abstract fell within the criteria, but there was insufficient

ies, 45.5%). Of these trials, 10 (9.9%) reported only the percentage

information on drug mechanism and/or trial phase, we reviewed the

of White participants without specifying percentages for any other

full text. A total of 506 records (clinical trial registrations or papers)

ethnoracial groups, and four (4.0%) included White participants only.

were assessed in full for eligibility. A total of 17 NCT registrations, 35

Race/ethnicity data was available for 58.2% (46/79) of the studies

EudraCT registrations, and one ANZCTR registration linked to pub-

that were registered as completed or early terminated. When looking

lished papers were retrieved manually. For three studies for which a

specifically at trials for which a published paper was available, 75.5%

published paper was available, we could not identify a clinical trial reg-

reported any race/ethnicity data (40/53). Different race/ethnicity cat-

istration.

egorizations were used across studies. Trials in Clinicaltrials.gov often

A total of 101 trials were included in this review. We extracted infor-

reported race and/or ethnicity according to the National Institutes

mation about these trials from 181 unique papers and clinical trial reg-

of Health/Office of Management and Budget (NIH/OMB) categories.

istrations, as well as from 21 full protocols that were attached to the

Although few papers explicitly reported using the NIH/OMB catego-

included papers or clinical trial registrations. The full protocols were

rization, a selection of these categories was often used in papers as

not publicly available for the remaining trials. The sample consisted of

well, whereas other categorizations were used very infrequently—one

67 phase II trials and 34 phase III trials, investigating 47 different drugs.

trial conducted across Asia, Europe, North America, and South America

The studies covered 2001 to 2019, during which 79 studies had fin-

reported numbers for “Caucasian,” “African,” “Hispanic,” “East Asian,”

ished recruitment, and 22 studies had not yet commenced or were reg-

and “West Asian” participants, and a paper about a trial conducted

istered as active/recruiting. A listing of the included papers and clinical

in the UK and Singapore reported the numbers of “Afro-Caribbean,”

trial registration numbers is provided in Table S1 in supporting infor-

“Asian,” and “Caucasian” participants.

mation. Several of the eligibility criteria were more prevalent in studies

The median reported percentage of White participants in all stud-

for which a full protocol was available as opposed to studies for which a

ies was 94.7% (interquartile range [IQR]: 81.0–96.7%). This percent-

full protocol was not available (see Text S2 in supporting information).

age of White participants was invariably high across both trials that

4
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FIGURE 1

Results of database searches and selection process

did and those that did not use specific eligibility criteria (see Table S2

.09). Of the studies for which a published paper was available 47.2%

in supporting information). Only seven studies reported the number

(25/53) reported the number of people who did not meet the eligi-

of participants with a Latinx (Latina/o) ethnic background (median:

bility criteria. Only 17.0% (9/53) specified which criteria most fre-

5.6%, IQR: 4.2–11.4%); specifically, 20.0% of the trials that included a

quently were the cause of participant exclusion. Although one study

North American site for which race/ethnicity data was available (7/35)

(NCT00105547) reported whether the excluded and included patients

reported the number of participants with a Latinx ethnic background.

differed on age and sex, none of the studies reported whether included

Data regarding (non-)Latinx background was often presented separate

and excluded participants differed on race/ethnicity.

from the number of participants in each racial group; it was therefore

Of the studies reporting race/ethnicity, none explicitly referred to

unclear how many participants with a Latinx background were included

socioeconomic status (SES), while 41.3% (19/46) reported on the par-

across racial groups (e.g., Latinx–White). The median percentage of

ticipants’ education level. We extracted the mean education level of

Black/African American participants was 1.2% (IQR: 0.4–1.7%), and the

the total sample for each of these studies and calculated the aver-

median percentage of Asian participants was 4.4% (IQR: 0.3–17.3%;

age of the reported means across placebo and intervention groups for

NB: three studies from Asia had samples consisting of 100% Asian par-

studies that did not report the total sample mean. The average mean

ticipants). The median percent of other or multiracial participants was

number of years of education across these studies was 13.3 years, and

0.9% (IQR: 0.0–1.9%).

a higher mean level of education was significantly correlated with a

We found no statistically significant relationship between the percentage of White participants and the study start year (ρ = –.26, P =

higher percentage of White participants included in the trial (ρ = .61,
P = .02).

5
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3.2

Eligibility criteria

up visits and allowing the patient to be accompanied by a “delegate” on
the other visits. Written informed consent (52.5%) and a contraindica-

3.2.1

Criteria related to medical conditions

tion to undergoing positron emission tomography (PET)/magnetic resonance imaging (MRI; 51.5%) were used as a criterion in the majority of

The frequency of exclusion criteria related to medical conditions is dis-

the included AD clinical trials.

played in the first columns of Table 1, ranked from most prevalent (top)

Of the 19 studies using an education criterion, eight studies also

to least prevalent (bottom). In the remaining columns to the right, we

allowed a work history consistent with no intellectual disabilities. For

present the prevalence of these medical conditions in several ethnora-

language fluency, most studies required fluency in the test language

cial groups to provide context for the potential impact on ethnoracial

(n = 11), in the “local” language (n = 11), or in English (n = 8), while

diversity of participants. In addition to ethnoracial groups within the

four studies allowed fluency in one of a number of languages. One

States19

(non-Latinx White, Latinx, non-Latinx Black, Ameri-

study allowed fluency in any language with sponsor approval, as long

can Indian/Alaska Native), we have included prevalence estimates from

as (1) staff were also fluent in that language, and (2) required study

the Indigenous Australian population20 as an example to illustrate the

documents were available in that language. A subset of studies (14.9%)

potential impact of eligibility criteria on an international scale (see note

included a criterion whether patients or patient–caregiver dyads were

to Table 1 for additional sources used to compile this table).

likely to complete the study in the opinion of the investigator; an oper-

United

Non-AD neurological diseases and (major) psychiatric disorders

ationalization of this criterion was not provided.

were used as an exclusion criterion in more than three quarters of
the included AD trials (Table 1, column 3), followed by cardiovascular disease (71.3%) and a history of cerebrovascular disease (68.3%).
The last five columns of Table 1 demonstrate that the prevalence of

3.2.3
Criteria related to diagnostic tests and
questionnaires

some medical conditions is higher in either non-Latinx Black US residents, Latinx US residents, American Indian/Native Alaskan US resi-

Cognitive tests, batteries, or screeners were used as an inclusion cri-

dents, or Indigenous Australians than in non-Latinx White US residents

terion in nearly all studies, with little variety in the tests that were

or non-Indigenous Australians: diabetes, major psychiatric disease,

used; the MMSE score was a criterion in over 90% of the stud-

cerebrovascular disease, renal disease, alcohol/substance use disorder,

ies (Table 3). Aside from the MMSE, a handful of other screening

liver disease, higher weight/body mass index (BMI), and human immun-

tests/short batteries were used, such as the Repeatable Battery for the

odeficiencey virus (HIV) diagnosis rates. For diabetes, studies some-

Assessment of Neuropsychological Status (RBANS21 ), the Alzheimer’s

times referred to specific HbA1c levels, but these levels varied substan-

Disease Assessment Scale-Cognitive Subscale (ADAS-Cog22 ), and the

tially from <6.0% to <9.0%; other studies included “insulin dependent”

Montreal Cognitive Assessment (MoCA23 ). Additionally, some stud-

diabetes, “poorly controlled” diabetes, or merely “diabetes.” Studies

ies used memory-specific tests: the Free and Cued Selective Remind-

with a BMI criterion mostly required participants to have a minimum

ing Test (FCSRT24 ), tests from the Wechsler Memory Scale–Revised

BMI of 18 or higher, but the upper cut-off value varied considerably

(WMS-R25 ), and the International Shopping List Test (ISLT26 ). One

from 28 to 40. Weight criteria specified a minimum weight of between

study used different cut-off scores for the test they used (WMS-R) to

35 and 45 kg (≈77–99 pounds), mostly with a maximum of 120 kg

correct for education (0–7, 8–15, and ≥16 years); none of the other

(≈265 pounds). For hepatic disease, specific alanine transaminase (ALT;

studies described different cut-offs based on demographic or sociocul-

1.5–3 times upper limit of normal, or ULN), aspartate transaminase

tural characteristics known to impact cognitive test performance (e.g.,

(AST; 1.5–3 times ULN), and/or bilirubin (1.5–2.5 times ULN) cut-

age, sex, ethnicity, quality of education, acculturation, etc.).

off levels were generally defined. For renal conditions, some studies

In addition to cognitive tests, roughly one-third of the trials used the

referred to specific levels of creatinine clearance, whereas others only

Clinical Dementia Rating (CDR27 ) global score as a criterion. A simi-

described “severe” renal disease, “impaired renal function,” or specified

lar proportion of studies used a measure of psychiatric symptoms as

dialysis requirement as the exclusion criterion.

part of the eligibility criteria. For depression, the 15-item version of
the Geriatric Depression Scale (GDS28 ) was used most often, as well as
the Hamilton Depression Rating Scale.29 The allowed range of scores

3.2.2

Criteria related to study procedures

for the GDS was relatively homogeneous across studies: the majority
of studies (n = 22, 88% of studies with GDS) included patients with a

Caregiver attendance was the most prevalent criterion related to study

score below 6 or 7, one study used the original 30-item version and

procedures (80.2%, see Table 2), which often specified that the same

used a cut-off score of ≤10, and two studies using a cut-off of <8 did

caregiver had to attend all study visits and sometimes that the care-

not specify whether the long or short version of the GDS was used. The

giver either had to live at the patient’s home or had to visit a minimum

Columbia Suicide Severity Rating Scale30 was used a few times, but the

number of times (range: <1–5 times/week) or hours per week (range:

majority of studies with a suicide risk criterion left the interpretation of

4–24 hours/week). Some studies were more flexible, for example, by

this criterion to the opinion of the investigator (in contrast with depres-

requiring the caregiver to accompany the patient only on key follow-

sive and cognitive symptoms).

6
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TA B L E 1 Frequencies of eligibility criteria related to medical conditions and prevalence of medical conditions in American and Australian
ethnoracial groups*
Criterion
frequency in all
trials (N = 101)

% in n-L White
Americans

% in Latinx
Americans

% in n-L Black
Americans

% in American
Indian and
Alaska Native

% in Indigenous
Australians†

Other neurological disease

81

80.2%

—

—

—

—

—

Psychiatric disorder

79

78.2%

6.9%

9.4%

9.7%

—

12% (9.6%)

Cardiovascular disease

72

71.3%

11.5%

8.2%

10.0%

14.6%

13% (1.2x)

Cerebrovascular disease

69

68.3%

2.6%

2.5%

3.9%

3.0%

—

- Hachinski ischemia scale
score >4

53

52.5%

—

—

—

—

—

- Cerebrovascular evidence
on MRI

48

47.5%

—

—

—

—

—

Childbearing/conception

62

61.4%

—

—

—

—

—

Unspecified systemic illness

62

61.4%

—

—

—

—

—

Alcohol or drug abuse

59

58.4%

8.4%

8.6%

7.4%

14.9%

18% (19%)

Vitals or lab abnormalities

53

52.5%

—

—

—

—

—

Infections/infectious diseases

50

49.5%

—

—

—

—

—

- HIV status‡

26

25.7%

4.8‡

16.4‡

39.2‡

7.7‡

5.5‡ (4.5‡ )

Liver disease

48

47.5%

1.7%

2.7%

1.1%

2.5%

15%-23%
(1.4x-2.1x)

Autoimmune disease

47

46.5%

22.0%

16.8%

21.0%

30.6%

10.0% (1.1x)

Renal disease

46

45.5%

2.0%

2.2%

3.1%

—

3.0% (≈3.7x)

Seizure disorder

44

43.6%

—

—

—

—

—

Cancer

41

40.6%

9.1%

4.2%

5.1%

7.1%

1.7% (1.5%)

Respiratory illness§

26

25.7%

7.5%§ ;
3.6%

6.0%§ ;
2.7%

9.1%§ ;
3.4%

9.5%;
—

18% (1.9x)
—

Endocrine dysfunction

25

24.8%

—

—

—

—

—

Brain/head trauma

25

24.8%

—

—

—

—

—

Diabetes¶

23

22.8%

8.6%¶ ;
13.0%

13.2%¶ ;
21.5%

13.1%¶ ;
19.6%

23.5%
—

11% (3.3x)
—

Weight or BMI cut-off

21

20.8%

31.0%

34.9%

38.0%

48.1%

37% (1.6x)

Gastrointestinal disease

18

17.8%

5.7%

4.3%

4.9%

8.3%

—

Excessive smoking (≥20
cigarettes per day)

9

8.9%

—

—

—

—

—

CNS inflammation

8

7.9%

—

—

—

—

—

Systemic inflammation

6

5.9%

—

—

—

—

—

Abbreviations: BMI, body mass index; CNS, central nervous system; HIV, human immunodeficiency virus; MR, magnetic resonance imaging; n-L, non-Latinx.
*2018 US National Health Interview study data19 and 2015 Australian Institute of Health and Welfare data are presented20 (unless otherwise specified),
providing prevalence rates for the following specific conditions within the broader categories specified in the first column: psychiatric disorders = moderate
to severe depressive symptoms (US78 ) versus feeling depressed (AUS); cardiovascular disease = any; cerebrovascular disease = stroke; alcohol or drug abuse
= substance dependence or abuse (US79 ) versus lifetime risky alcohol consumption (AUS); infections – HIV status (US80 ); autoimmune disease = arthritis
diagnosis; renal disease = weak or failing kidneys (USA) versus chronic kidney disease stages 3-5 (AUS); liver disease = any (US) versus abnormal ALT/GGT
(AUS); cancer = any; weight or BMI = obesity; gastrointestinal disease = ulcers (duodenal, stomach, peptic).
†
In parentheses: times increased risk compared to non-Indigenous Australians or prevalence rate in non-Indigenous Australians.
‡
Diagnosis rate per 100,000.
§
Respiratory illness = current asthma (top) and chronic bronchitis (bottom).
¶
Diabetes = diagnosed (top) versus diagnosed and undiagnosed combined (bottom81 ).
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TA B L E 2 Frequencies of criteria related to undergoing study
procedures
Criterion frequency in
all trials (N = 101)
Caregiver attendance

81

80.2%

Written informed consent

53

52.5%

Contraindication to MRI/PET

52

51.5%

Adequate sensory abilities

42

41.6%

Language ability

35

34.7%

Residence in the community

35

34.7%

Caregiver consent

28

27.7%

Education requirement

19

18.8%

Reading or writing ability

19

18.8%

Determined likely to complete

15

14.9%

4

4.0%

Recent hospitalization

Abbreviations: MRI, magnetic resonance imaging; PET, positron emission
tomography.

TA B L E 3 Frequencies of neurocognitive and neuropsychiatric
screening tests and measures

F I G U R E 2 Changes in Mini-Mental State Examination (MMSE)
upper and lower cut-off scores (midpoint in dotted line)

Diagnostic tests and screeners: the use of the MMSE, CDR, and GDS
over time
Additional Cochran-Armitage trend analyses of the use of the MMSE

Criterion
frequency in
all trials (N =
101)

or without an MMSE-eligibility criterion (Z = 0.14, P = .89); that is, the
MMSE cut-off scores were not used significantly less (or more) often
with time. As displayed in Figure 2, the cut-off score for the MMSE

COGNITIVE TESTS
MMSE

revealed that the study start year did not differ between studies with

increased over time (MMSE lower limit ρ = 0.53, P < .001; MMSE upper

91

90.1%

Memory-specific test*

7

6.9%

RBANS

4

4.0%

ADAS-Cog

3

3.0%

significant increase or decrease in the use of the GDS by study year (Z =

MoCA

1

1.0%

0.0, P = .99); the CDR, however, was used significantly more frequently

scores narrowed over time (ρ = –0.44, P < .001). Similar to the MMSE,
the Cochran-Armitage trend test showed that there was no statistically

in later years (Z = –2.48, P = .01).

GLOBAL & FUNCTIONAL MEASURES
CDR

limit ρ = 0.48, P < .001). Furthermore, the range of allowed MMSE

36

35.6%

Eastern Cooperative Oncology Group status

1

1.0%

FAQ

1

1.0%

25

24.8%

Hamilton Depression Rating Scale

6

5.9%

Other depression instrument

1

1.0%

were defined; and (3) discover whether the use of criteria related to

C-SSRS

5

5.0%

cognitive and neuropsychiatric instruments changed over time. The

14

13.9%

results showed that study samples were predominantly composed of

4

DISCUSSION

PSYCHIATRIC ASSESSMENTS
Geriatric Depression Scale

Other/unspecified suicide or self-harm risk scale

Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment ScaleCognitive Subscale; C-SSRS, Columbia Suicide Severity Rating Scale; CDR,
Clinical Dementia Rating; FAQ, Functional Activities Questionnaire; MMSE,
Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment;
RBANS, Repeatable Battery for the Assessment of Neuropsychological
Status.
*Includes Free and Cued Selective Reminding Test (FCSRT), Wechsler Memory Scale-Revised (WMS-R), and International Shopping List Test (ISLT).

In this systematic review, we aimed to (1) investigate the level of participant diversity in AD clinical trials targeting Aβ and tau; (2) identify which eligibility criteria have been used and how these criteria

White individuals, and ethnoracial diversity levels did not show a significant increase (or decrease) over time. Some of the most frequently
reported criteria were the exclusion of participants with non-AD neurological disease, psychiatric illness, cardiovascular and cerebrovascular disease, obligated caregiver attendance, and cognitive impairment
as defined by a specific score on the MMSE. The MMSE was used in an
overwhelming majority of cases as the main cognitive eligibility criterion and was used consistently over time, with cut-off scores increasing
over the years, but with the range of allowed scores decreasing over the
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TA B L E 4

Issues with eligibility criteria of clinical trials and recommendations

Issue/criterion

Recommendations

Overarching issues
-Race and ethnicity often were not reported
-Current race/ethnicity definitions not globally suitable
-It is unclear how many diverse patients are invited,
screened, and excluded
-It is unclear which criteria lead to exclusion
-Criteria from phase II copied to and expanded on in phase III

-Improve reporting
-Critically examine and improve definitions of race/ethnicity
-Improve reporting
-Improve reporting
-Revisit/revise all criteria in moving from phase II to phase III

Criteria related to medical conditions
-Imprecise/unspecific definitions of medical conditions
-Variation in cut-offs for specific medical conditions
-It is unclear if race corrections should be used or not
-Exclusion of all patients with a medical condition regardless
of past/present health status
-Questionable safety of drugs for patients with medical
conditions due to exclusion

-Use validated, internationally recognized clinical classifications (of disease staging)
-Organize expert consensus meetings to determine appropriate cut-offs in AD research
-Organize expert consensus meetings to determine whether and when to apply race
corrections
-Include more patients who can safely participate, for example, persons living with HIV
who are medically stable and have a non-detectable viral load
-Use expansion cohorts to study safety

Criteria related to study procedures
-Language fluency as a barrier to participation
-Lower educated individuals often excluded

-Risk of compliance stereotyping if “likely to complete” is not
defined
-Caregiver attendance as a barrier to participation

-Written informed consent as a barrier in persons with
limited literacy/education

-Allow fluency in any language if adapted materials and staff speaking that language are
available
-Allow persons with a work history consistent with no intellectual disabilities (ID) to
participate
-Investigate other ways to screen for ID
-Define “likely to complete” before trial
-Allow others to accompany patient on subset of visits
-Plan appointments outside business hours
-Explore remote interviewing options
-Explore alternatives for written informed consent, such as video informed consent

Criteria related to neurocognitive and neuropsychiatric
measures
-MMSE is unsuitable for diverse populations
-CDR may be biased due to cultural differences

-Consider alternative, more widely applicable tests
-Use different MMSE cut-offs depending on education and other relevant variables
-Consider adaptations to the instrument/questions
-Provide additional training to staff

Abbreviations: AD, Alzheimer’s disease; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination.

years. The criteria related to medical conditions and study procedures

was described, it was presented separately from the numbers by racial

often were not well operationalized and cut-off scores were often wide

group. It was therefore not possible to determine how many Latinx

ranging. In addition to these main aims, our goal was to discuss how

versus non-Latinx participants were included, and whether these pro-

these eligibility criteria may have affected diversity levels. In the fol-

portions may have changed over time. However, based on the studies

lowing paragraphs, we will discuss the main outcomes of this review

that did report the number of Latinx participants, as well as the data

and provide recommendations for future clinical trials, an overview of

from Black, Asian, and other racial groups, it seems unlikely that Lat-

which can be found in Table 4.

inx participants were well represented. This lack of diversity, as well as

We could not retrieve race/ethnicity data for more than half of the

the underreporting of Latinx background are particularly notable for

studies included in this review; for those studies for which a paper

studies with a North American site (79.2%), given the rapidly increasing

was published, a little over three quarters reported race/ethnicity data.

diversification of the United States during this review period. Whitfield

This is somewhat higher than in a review of cholinesterase inhibitors

et al.31 describe how, as the ratio of White participants to other eth-

and memantine randomized controlled trials (59.2%5 ). The studies that

noracial groups increases, the statistical power to detect group differ-

reported race/ethnicity data included an overwhelming majority of

ences decreases drastically, and samples will typically have to include

White participants (≈95%), and no significant increase or decrease in

a larger proportion of diverse ethnoracial participants than a repre-

this ratio was observed over time. For most trials, data regarding Lat-

sentative sample of the general population (e.g., more than 15% Black

inx ethnicity was not reported, and in the handful of cases in which it

participants in the sample). As it stands, the limited percentage of
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ethnoracially diverse individuals precludes sufficiently powered anal-

materials are available in that language and there is a staff member

yses of safety and efficacy across ethnoracial groups. In addition, cur-

available who speaks the language to the degree necessary for cogni-

rently used racial/ethnic categories themselves may need to be revised

tive testing—as was allowed in one trial (NCT00676143). This would,

to fully represent global diversity—for example, categorizing all indi-

however, require the development/adaptation and validation of test

viduals from Europe, North Africa, and the Middle East as “White” does

materials across a number of languages. In addition, it may be worth-

not do justice to the diversity within and between persons originating

while to investigate if assessment with experienced formal interpreters

from these regions.

could be a viable option at study sites where the population is excep-

Our results showed that trials targeting Aβ or tau in AD often pro-

tionally diverse.

vide unclear definitions of their eligibility criteria; these imprecise def-

Regarding education, a minimum of 6 years of formal education was

initions, such as “diabetes” or “impaired renal function” (not further

often used as a criterion—sometimes stating this was to ensure that

specified), likely result in the exclusion of all or most patients with

patients with intellectual disabilities were not included. This criterion

a specific medical condition. When specific ranges on indices of cer-

is problematic for several reasons; first, many diverse elderly patients

tain medical conditions were provided, such as BMI or ALT/AST lev-

across the world did not receive any formal education during child-

els, the allowed ranges differed substantially between studies. There

hood due to reasons other than intellectual disabilities—such as a lack

thus seems to be a lack of consensus on how these conditions are best

of financial means or a large geographic distance to educational facili-

defined in the context of Aβ and tau trials. These ill-defined eligibil-

ties (e.g., in first generation immigrants in Europe). Second, mandatory

ity criteria may particularly affect the inclusion of underrepresented

primary education across the world has historically been variable—

populations that are characterized by health disparities. Kim et al.32

although some countries required 6 years of primary education, others

made several suggestions to broaden inclusion criteria in oncology tri-

may have required only 4 or 5. Therefore, years or level of education

als that may provide inspiration for AD trials. One of these recommen-

cannot serve as a suitable proxy for intellectual disabilities in diverse

dations is to include persons living with HIV (PWH) based on current

patients. Some studies acknowledged these barriers by allowing people

and past CD4+ and T-cell counts instead of excluding all PWH—unless

with a work history consistent with no intellectual disabilities to par-

antiretroviral therapy is expected to interact with the investigational

ticipate in the study. Future studies should focus on developing ways to

product. Additionally, one might take into consideration whether PWH

screen for intellectual disabilities that do not result in the exclusion of

are medically stable and whether they have a (non-)detectable viral

patients without intellectual disabilities who had limited access to for-

load. Furthermore, Kim et al.32 provided examples of how to improve

mal education.

the clarity of the definitions used in clinical trials eligibility criteria,

Several studies included a criterion that patients should be likely to

such as the use of validated clinical classifications (of disease staging)

complete the study. However, the interpretation of this criterion often

as opposed to more generic definitions.

was not defined, requiring the investigator to make this judgment call.

With regard to the impact of criteria related to medical conditions

Although such a criterion may be necessary to prevent costly missed

on the inclusion of ethnoracially diverse groups specifically, it is still

visits in clinical trials, especially for studies using PET-ligands, likeliness

uncertain if, how, and when race corrections should be used to eval-

to complete should be well defined at the outset. For example, a pro-

uate various clinical laboratory results as indicators of specific medi-

tocol may state that the patient and caregiver should complete a first

cal conditions, such as indicators of kidney functioning33 and several

run-in period of a specific number of screening visits fully compliant

other common laboratory values.34 Although such race corrections

with the specified study procedures and in line with a specified time

could potentially make the process of inclusion in clinical trials more

schedule. If this criterion is left undefined, it may prove problematic, as

inclusive, they may also inadvertently perpetuate or amplify existing

studies have indicated that participant selection may be influenced by

disparities.35 The field is in need of expert guidance to reach a consen-

implicit bias of the clinicians, that is, compliance stereotyping.37

sus on whether and when to apply these race corrections.

More than three quarters of the studies required some form of care-

Criteria related to undergoing study procedures were commonly

giver participation, often explicitly stating caregivers had to engage

part of the eligibility criteria. In the following paragraphs, the eligibility

in frequent contact with patients—one study required caregivers to

criteria related to language, education, caregiver attendance, written

spend at least 24 hours per week with the patient. In some diverse

informed consent/reading and writing abilities, and whether patients

ethnoracial groups, the main caregiver is often an adult child, rather

are considered likely to complete the study, are discussed in more

than a spouse,38–40 and previous research has indicated that adult chil-

detail, specifically in the context of the inclusion of diverse individuals.

dren are less likely than spouses to be eligible to participate alongside

First, language requirements, such as fluency in the English lan-

patients in dementia clinical trials.41 Adult–child caregivers are more

guage, were included in more than one third of the clinical trials.

likely to still be active in the workforce,39 potentially limiting their

Depending on their definition, specific language requirements may lead

opportunities to engage in frequent study visits due to the practical and

to disproportionate exclusion of individuals from underrepresented

financial burden of missed work. Researchers may provide more flexi-

populations. The lack of guidance on how to handle language barriers in

bility by allowing others to accompany patients on a subset of visits; by

clinical trials was acknowledged as a problem by multicenter research

having appointments taking place outside of weekday business hours;

ethics committees in the UK.36 A more inclusive solution may be to

or by exploring options for remote administration of interviews, such

allow fluency in any preferred language, as long as the required test

as over the phone or via video calls.39
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More than half of the AD clinical trials in this review explicitly

trial. As selection bias is often present in reliability/validity studies—

required written informed consent. Although this currently seems

for example, by excluding persons with low education levels or limited

to be the standard, requiring written informed consent will lead to

language fluency—it may be necessary to specifically check the demo-

the exclusion of people with low literacy skills—either because these

graphic characteristics of these original study samples to ensure they

patients will not be asked, or because they will be hesitant to sign a

reflect the intended trial sample. At a minimum, trials can be made

document they have difficulty understanding. Globally, ≈781 million

more equitable by using different cut-off scores for groups with differ-

adults are illiterate, with a high prevalence in lower- and middle-income

ent levels of education in cognitive screeners and memory tests, as was

countries,42 although disparities in literacy are also prevalent in some

done by one trial in this review (NCT00890890).

underrepresented populations in high-income countries. For example,

In addition to the MMSE, this study showed a rise in the use of the

so-called “guest workers” in Europe often received little if any for-

CDR as an inclusion criterion. The CDR has considerable merits, but

mal education,43,44 and Latinx adults—and to a lesser degree Black

researchers and clinicians need to be aware of possible cultural differ-

and American Indian/Alaska Native adults—in the United States were

ences that may bias the results, such as (1) downplaying of cognitive

overrepresented in the “below basic” level on the National Assessment

symptoms out of respect for older family members, (2) different per-

of Adult Literacy.45 To facilitate the enrollment of underrepresented

ceptions of what “normal” daily functioning may entail, (3) the need

populations, informed consent procedures will have to be tailored to

for adaptations to questions relating to hobbies that may be uncom-

patients and caregivers with low literacy skills. Over two decades ago,

mon in some groups—for example, crossword puzzles—and social or

the US Food and Drug Administration (FDA) described the possibility

cultural practices, (4) the potential influence of traditional gender roles,

of non-written consent procedures in illiterate English-speaking sub-

and (5) the potential influence of limited literacy on some activities of

jects, in which an impartial third party cosigns the consent document,

daily life.54 Aside from the extensive training that is already needed to

recording.46

preferably with a videotape

A recent study in a differ-

administer the CDR in a reliable and valid way in the general popula-

ent medical field (cardiology/endocrinology) has indicated that using

tion, it is likely that additional training and/or adaptations to the instru-

a video informed consent procedure can increase the enrollment of

ment itself are needed to make it more suitable for the assessment of

patients from underrepresented populations.47

diverse populations across the globe.

As an additional exam-

ple, in India, audiovisual recording of the informed consent procedure

In addition to these specific recommendations pertaining to criteria

has been mandatory since 2013, and standard operating procedures

related to medical conditions, undergoing study procedures, and cog-

have consequently been developed.48 AD research would benefit from

nitive screeners and questionnaires, some general recommendations

efforts to incorporate alternatives to written informed consent devel-

may further improve inclusion of underserved populations in AD clini-

oped in other research areas that include diverse and vulnerable popu-

cal trials. In the design phase, the FDA55 specifically recommends revis-

lations, as well as from initiatives examining the feasibility of integrat-

iting and revising the criteria when moving from a restrictive phase II to

ing such approaches in AD research.

a more inclusive phase III trial.32,55 Furthermore, they encourage the

Regarding cognitive screening tests and questionnaires, we found

inclusion of samples known as “expansion cohorts” in trials—consisting

that the MMSE was used almost invariably as an inclusion criterion,

of patients with specific comorbidities that may not fit the inclusion cri-

and its use remained stable over time, with cut-off scores even increas-

teria for the main study—to determine the safety of doses in these pop-

ing over the years. This is notable, given the fact that Schneider et al.14

ulations as well.32 Aside from changes to the trial design, more insight

warned about the use of the MMSE in dementia trials in 1997. There

can be gained into the mechanisms behind the underrepresentation of

is an abundant literature describing how MMSE-scores are substan-

diverse patients in clinical trials, if studies were to report the ethnora-

tially influenced by literacy and education49–51 and likely also by cul-

cial characteristics of all patients that (1) were considered for eligibil-

tural background.50 In particular the subtests of orientation to time

ity, (2) were invited, (3) were screened, and (4) were excluded/screen

and place, serial 7s, figure copy, writing, and reading will be substan-

failed. In addition, reports should provide specifications regarding the

tially influenced by someone’s educational and cultural

background.52

eligibility criteria that were most often the reason for exclusion.

Developing alternatives to written informed consent will only solve

Although not technically part of the CONSORT (Consolidated Stan-

half of the problem as long as the cognitive tests used for screening and

dards of Reporting Trials) guidelines,56 a short summary of the main

to measure primary and secondary outcomes require reading and writ-

reasons for exclusion may provide valuable insights to researchers

ing skills. Moving forward toward more valid and inclusive global clin-

on the eligibility criteria that have the strongest effect on eligibil-

ical trials will entail using other cognitive tests that are more suitable

ity. This information was only provided in a handful of studies in this

for diverse populations. For instance, the Rowland Universal Dementia

review, and none of the studies specified whether there was a dis-

Assessment Scale (RUDAS53 )—a test to assess the general level of cog-

proportionate exclusion of patients from underrepresented popula-

nitive impairment—or the International Shopping List Test26 —for the

tions. It therefore remains unclear whether there was a dispropor-

inclusion of patients with memory impairment specifically—may be rel-

tionate exclusion of patients from these groups based on overly strict

evant options for further study. Before any instrument is selected for

eligibility criteria, or whether these patients were not invited in the

a clinical trial, it is imperative that a thorough review of the literature

first place or did not consent to study participation after invitation.

is carried out to determine whether the instrument is a valid and reli-

For example, patients from underrepresented populations may expe-

able measure of cognition in all groups that are to be included in the

rience geographical, financial, or logistical barriers that prevent them
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from participating in research.55,57 Additionally, recruitment strategies

systemic and striking when zooming in on elderly populations specifi-

need to be tailored to suit the needs of underrepresented populations,

cally. For example, the prevalence of overweight and obesity in indige-

such as by investing in community-outreach programs, trust-building

nous populations in Australia is 35% in those aged 15 to 17, but rises

initiatives, and cultural-sensitivity training.10,36,58,59 Financial support

to 80% in those 55 and over.20 Although we only showed data from

from funding agencies and/or the trial sponsor to facilitate such ini-

the United States and Australia, similar health disparities are observed

tiatives may be needed. In addition, more general financial or regula-

in populations outside those two countries, such as across different

tory incentives from funding organizations or governmental bodies to

ethnoracial groups in Europe—particularly in the prevalence of dia-

actively enroll patients from underrepresented populations may fur-

betes, stroke, hypertension, and cardiovascular disease,67–69 but also

ther improve inclusion, for example, similar to the changes in the field

in kidney disease.70,71 Fourth, it is important to note that the data

of pediatrics, in which the Pediatric Research Equity Act (PREA) now

based on Latinx American samples is based on a pan-Latinx construc-

requires manufacturers to complete studies in children if a substantial

tion of this population. These studies did not account for the signifi-

number of children is expected to use the drug.60

cant within-group variance that has important implications for health

Although this review specifically examined race/ethnicity, we

disparities and cognitive test performance (e.g., origin/nativity [Mex-

acknowledge that race is a social construct and that health dispari-

ican, Puerto Rican, etc.], acculturation). Fifth, we only focused on Aβ

ties are often driven by social determinants of health, such as edu-

and tau trials in this review. Although many of these recommendations

cation, literacy, socioeconomic status, racially patterned social stress,

can likely also be applied to other types of trials across neurodegenera-

and access to care.61–63 Although some trials in this review with

tive diseases, such as lifestyle trials like World-Wide FINGERS,72 some

race/ethnicity data reported the education level of the included partic-

of these trials will come with their own unique challenges—such as a

ipants, none mentioned SES. This limited reporting of social determi-

lack of suitable cross-cultural instruments measuring social cognition,

nants of health is in line with a previous review in symptomatic treat-

language, and behavioral changes in frontotemporal dementia trials73

ment of AD, in which no studies reported on variables such as lifetime

as well as issues regarding the applicability of the diagnostic criteria

occupation, individual/household income, or wealth, and few stud-

for primary progressive aphasia subtypes across global languages, such

It remains unclear how these variables may have

as Chinese.74 Last, we were unable to determine the direct effect of

affected enrollment of diverse participants in the trials included in this

each criterion on the representation of diverse individuals using infer-

review; however, participants are often recruited in memory clinics,

ential statistics. Several factors precluded such analyses, such as the

and these facilities may not be accessible to some underrepresented

fact that some criteria were used either very infrequently or invariably

groups, for example because of limited health literacy,65 or because

(e.g., the MMSE, Table S2), as well as the fact that race/ethnicity data

medical care is expensive and insufficiently covered by insurance.66

was not reported for each global region/country specifically, precluding

ies on

education.64

Several limitations to this review should be mentioned. Although

any comparisons of the makeup of the study samples with a priori dis-

we did not exclude studies based on the language in which the record

ease estimates in the general populations in these countries/regions.

was written, our study did not identify any articles that were not writ-

The contribution of each individual eligibility criterion to the under-

ten in English. Therefore, some local trials may have been missed. Sec-

representation of diverse individuals across trials therefore remains

ond, race/ethnicity data was not available for a substantial number

unclear—even more so given the underreporting of the main reasons

of studies, and the full protocols describing all eligibility criteria were

for exclusion.

only available for about one fifth of the included trials. As can be seen

Both federal law (Public Health Service Act §492B75 ) and NIH

in the supporting information, the frequencies of the eligibility crite-

policy76 require studies involving human subjects to address the

ria may differ between studies with and without a full protocol avail-

inclusion of “minorities,” and Alzheimer Europe77 similarly calls upon

able, and the rates we presented in this review may be an under-

researchers, ethics committees, and funders to address inequity in

estimation of the actual frequencies. For example, it seems unlikely

research. This review illustrates that there is a continuous, systemic

that only slightly more than half of the clinical trials required writ-

underrepresentation of ethnoracially diverse groups in AD clinical tri-

ten informed consent, particularly as the studies without such a cri-

als. To generalize safety and efficacy data of AD clinical trials to the gen-

terion did not describe any alternative consent requirements. Like-

eral population, more diverse individuals need to be enrolled, and mod-

wise, trials that did not report race/ethnicity data may have included

ifying or changing the eligibility criteria in AD clinical trials may play a

even fewer diverse participants—or, less likely, more—than the studies

key role in reaching this goal.

that did report race/ethnicity data. Third, in this review, we presented
data from diverse ethnoracial populations in Australia and the United
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